Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply
Resilience and Lilly expand strategic partnership first established in 2023 Investment will significantly increase U.S. production of Lilly’s...
BLOG
Read on
Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities
BLUE ASH, Ohio, June 18, 2026 – Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today...
Problem Solving for Aseptic Filling
How the thoughtful adoption of new technology can both problem-solve and future- proof critical processes in biomanufacturing For any forward-facing...
Leveraging Partnerships to Achieve Cell Therapy Success
What impact can partnerships have in cell therapy commercialization success? Eytan Abraham at Resilience discusses the need for a modernized...
Master Cell Banks: Laying the Foundation to Final Product Success
Consider our top 5 FAQs when it comes to MCBs Master cell banks (MCBs) are a critical starting material that lay the foundation for the scale-up and...
Looking Ahead: What Does the Future Have in Store for Nucleic Acid-Based Therapies?
A Q&A with Aaron Larsen Aaron Larsen is the Technical Head for the Nucleic Acids Franchise with Resilience. He began working with nucleic acids back...
Cell Therapy – What Does It Take To Become a Mainstream Option
While cell therapies are still a small segment of therapeutics, the landscape is rapidly changing — with over 1,000 ongoing clinical trials and...
